Insights
Notes on AI work in regulated environments.
These are not generic AI trend pieces. They are short, opinionated notes on where projects get stuck, what governance work actually matters, and what regulated teams usually underestimate.
Pharma AIMarch 7, 2026
Pharma is spending more on AI. The real bottleneck still isn’t the model.
Why data governance, not model quality, is still the thing slowing AI adoption inside pharma and regulated life sciences teams.
Read the governance note
Regulated OperationsMarch 8, 2026
Validation is becoming the hidden cost of AI in regulated companies.
Why change control, documentation, and validation workload keep quietly killing otherwise promising AI projects.
Read the validation note